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Abstract
Background: Progesterone receptor act as ligand-inducible transcription factor in the respective
target cells by binding to specific progesterone response elements in the promoter of the target
genes. However, despite the lack of the classical progesterone response elements on matrix-
metalloproteinase-2 promoter, progesterone has been shown to decrease the activity of this
promoter
Presentation of the hypothesis: It has recently been suggested that in addition to interacting
with their classical co-activators and co-repressors, progesterone receptor are capable of binding
to several transcription factors. By interacting with other classes of transcription factors,
progesterone receptor is capable of transcriptional activation through the transcription factors
cognate DNA binding site.
Testing the hypothesis: Exploring transcription factors and transcription binding sites,
interacting with the progesterone receptor in modulation of the matrix-metalloproteinase
promoter.
Implications of the hypothesis: Identification of additional endogenous progesterone target
genes makes it possible to further explore the signaling mechanisms by which the hormone
regulates biological actions. Furthermore, the concepts of ligand-driven conformational diversity
and selective tissue actions can be exploited in the future for drug development which selectively
regulate orphan receptors from the nuclear receptor family.
Background
The physiological effects of progesterone are classically
mediated by interaction of the hormone with the two clas-
sical intracellular progesterone receptor (PR) isoforms PR-
A and PR-B [1]. Both isoforms, encoded by a single gene
independently regulated by separate promoter, regulate
different subsets of genes [1,2].
PR acts as ligand-inducible transcription factor in the
respective target cell by binding to specific progesterone
response elements (PRE) in the promoter of target genes
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[1,2]. These transcriptional interfaces respond not only to
endocrine, but also to paracrine and perhaps autocrine
signals [1-3]. Multiple regulatory mechanisms involving
selective expression of the cognate receptor and its bind-
ing to specific hormone response elements, assure that
progesterone signal transduction will result in an accurate
regulation of the respective gene networks [1-4]. The type
of PR-isoform dictates the proteins complex composition
to include various transcription factors, co-activators or
co-repressors responsible for specific chromatin remode-
ling [5]. When expressed in equimolar ratios in cells, the
PR-A and PR-B proteins binds to the PRE and dimerize as
three distinct species: A:A or B:B homo-dimers or A:B het-
erodimers. Each combination can modulate different sets
of genes. Progesterone receptor isoforms are members of
a larger family of structurally related nuclear receptor
(NR) super-family of transcription factors [6]. The PR iso-
forms are characterized by organization into specific func-
tional domains and are conserved, to differing degrees,
between species and family members [6,7]. PR contains
three functional domains including the N-terminus, a
centrally located DNA binding domain (DBD), and C-ter-
minal ligand binding domain (LBD) [7]. Three-dimen-
sional atomic structures of isolated DBD and LBD have
revealed common motifs for these regions. The N-termi-
nal domain is the least conserved region among family
members with respect to both length and amino acid
sequence. The N-domain is functionally important, as it is
required for full transcriptional activity of steroid hor-
mone receptors and for many cell- and target gene-specific
responses. Steroid receptors have transcription activation
domains (AF) located in the N-terminal domain (AF-1)
and in the C-terminal LBD (AF-2). These are autonomous
transferable domains required for the DNA bound recep-
tor to transmit a transcriptional activation response and
they function as specific binding sites for co-activators.
The activity of the highly conserved AF-2 is hormone-
dependent and requires release of the heat shock proteins
leading to the conformational change and receptor dimer-
ization [6-8]. The amino terminal region among members
of the super-family is the most hyper-variable region in
terms of both size and amino acid sequence. Studies on
human PR indicate that PR-A isoform is lacking the first
164 amino acids in the amino-terminal. In the PR-B iso-
form this region contains, in addition to AF-1, a third
transactivation domain (AF-3) that recruits not only co-
activator proteins but also serve as an inhibitory domain
responsible for recruitment of transcriptional inhibitory
co-repressor proteins. The presence of the AF-3 domain in
the PR-B, and its lack in other isoforms is likely to be
responsible for the differential transactivation properties
that contribute to the complete repertoire of physiological
responses to progesterone [6-8]. Detailed structure/func-
tion studies on the human PR isoforms indicate that PR-B
functions as a ligand-dependent transactivator in contrast
to PR-A, which in some contexts, acts as a ligand-depend-
ent transcriptional repressor of PR-B as well as of other
steroid hormone receptors [6-8]. Progesterone receptor
regulates transcription by recruiting co-activators or co-
repressors complexes to target gene promoters. Co-activa-
tors recruited by ligand-bound nuclear receptors (NR)
include members of the SRC family of co-activators, such
as SRC-1, SRC-2 and SRC-3, [9-11]. These proteins serve
as adaptors for the transcriptional activity of different NRs
through conserved motifs termed NR boxes [9-11]. The
SRC family has been studied extensively [9-11]. Motifs
within the receptor-interacting domain of SRCs have been
demonstrated to determine co activator preferences for
specific NRs, while the transcriptional activation domains
of SRCs mediate interactions with histone acetyltrans-
ferases (HATs) responsible for chromatin remodeling [9-
11].
Contrary to the large number of co-activators of progester-
one receptor, only two well characterized co-repressors
have been described, the SMRT (silencing mediator for
retinoid acid receptor), and an orphan nuclear receptor
DAX-1 (dosage sex reversal, adrenal hypoplasia congenita
critical region on the X chromosome, gene 1) [12,13].
Both co-repressors were described as effective repressors
of agonist-dependent activity of PR. SMRT represses PR in
the presence of either progestins or progesterone receptor
antagonist RU486 [12,13]. DAX-1, however, repressed PR
in the presence of progestins, but exhibited opposite co-
regulation patterns when bound to the progesterone
receptor antagonist [12,13]. Recently it was documented
that in addition to interacting with their classical co-acti-
vators and co-repressors progesterone receptor can bind to
several transcription factors [14-16]. Direct interaction
between activated PR and the proinflammatory factor,
nuclear factor-B, has been shown to result in reciprocal
transcriptional repression [14-16]. Functional interaction
between liganded PR and C/EBPβ was found to mediate
the enhancement of dPRL (decidual prolactin) promoter
activity in response to progestin treatment. In-vitro associ-
ation studies have demonstrated that both PR isoforms
physically interact with the C/EBPβ isoforms, liver-
enriched activator protein (LAP) and liver-enriched inhib-
itory protein (LIP). It was documented that PR-A
enhances LAP trans-activation of a model C/EBP-respon-
sive reporter construct, as well as the proximal dPRL pro-
moter, and PR-B-dependent transcription of promoters
driven by palindromic PRE is enhanced by LIP. These data
reveal the unique complexity of C/EBPβ and PR cross-cou-
pling [14,15].
The basic transcription element-binding protein (BTEB1),
a member of the Sp/Krüppel-like family (KLF) of tran-
scription factors [15,16] is described also as PR-B interact-Journal of Experimental & Clinical Assisted Reproduction 2006, 3:4 http://www.jexpclinassistreprod.com/content/3/1/4
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ing protein. In the presence of ligand-activated PR-B, the
functional complex formed between the PR-B dimmer
and BTEB1 favored the induction of PRE-containing pro-
moters. BTEB1 has no effect on PR-A transactivation but
enhances PR-A-mediated repression of PR-B transcrip-
tional activity. BTEB1 was found to cooperate with the
transcriptional integrator CREB-binding protein (CBP)
[14-16] enhancing the transcriptional activities of ligand-
bound PR-B and un-liganded PR-A. In addition, Sp1 tran-
scription factor was also found to interact with PR-B in
specific transcriptional regulation [14-16].
This manuscript describes, using trophoblast as a model,
a hypothesis suggesting that progesterone can regulate
genes lacking PRE in their promoter region via alternative
mechanism.
Presentation of the hypothesis
It is generally accepted that progesterone affects matrix
metalloproteinase (MMP) secretion in many reproductive
tissues [17-19]. Several studies have demonstrated that
progesterone restrains endometrial tissue breakdown by
inhibiting the stimulation of the matrix metalloprotein-
ases [17-21]. In the presence of progesterone, secretion of
MMP9 from trophoblasts was reduced [20]. In early
human trophoblast cells (up to 8 weeks of gestation) pro-
gesterone inhibits MMP2 expression by direct transcrip-
tional regulation [21]. Differential progesterone receptor
profile was documented with the dominance of PR-B in
early trophoblast and dominance of PR-A in late trophob-
last (between 9 to 12 week gestation). This differential
profile is compatible with the inverse effect of the proges-
terone on the two cell populations decreasing invasion
and gelatinase expression in the early human trophoblast
(up to 8 weeks of gestation) and increasing invasion and
gelatinase expression in the late human trophoblast
(between 9 to 12 week gestation). Decrease in MMP2 pro-
moter activity in early trophoblast cells exposed to proges-
terone suggests that MMP2 expression is regulated by
progesterone also at the transcriptional level [21]. Several
studies mapping the potential response element on
MMP2 promoter suggested the existence of eight major
response elements. However, it appears that the promoter
of MMP2 lacks PRE [22,23], thus, novel mechanism by
which progesterone might inhibit MMP expression is sug-
gested. In addition to direct transcriptional activation
through binding of the activated receptor with its cognate
DNA response element (Figures 1A), PR is also capable of
transcriptional activation interacting with other classes of
transcription factors on their cognate DNA binding site
(Figures 1B). Thus, binding to consensus PRE may not
necessarily be required for P-responsiveness of target
genes. These dual mechanisms enable the differential role
of each receptor in the transcriptional regulation of spe-
cific gene either by direct binding or by interaction with
specific transcription factors to specific binding regions in
the promoter. After looking into the potential response
element on MMP2 promoter two potential transcription
factors family members are suggested based on previous
published data: C/EBP and SP-1. Transcription factors
from both response elements were found to interact with
PR-B as well as PR-A. We suggest that in such cases proges-
terone serves as co-activator or co-repressor. This pro-
posed novel role for progesterone receptor in
transcriptional regulation enlarges the poolof gene candi-
date to be regulated by progesterone.
Testing the hypothesis
In order to test the proposed hypothesis two sets of exper-
iments should be conducted. Based on the publication of
the inhibitory effect of progesterone on MMP expression
and the lack of PRE in MMP promoter it is preferable to
use one member of this family as a target gene to test the
hypothesis. We propose to use trophoblast cells as a
model for progesterone regulation of MMP promoter reg-
ulation.
Specific aim 1: Localizing progesterone response region/s 
in MMP promoter
Part A
In order to identify possible binding sites in MMP pro-
moter which mayparticipate in progesterone regulation,
we will conduct transient transfection with a series of
mutated or deleted constructs of the human MMP pro-
Hypothesis model for PR Transcriptional activation Figure 1
Hypothesis model for PR Transcriptional activation. 
A: Transcriptional activation through classical mechanism on 
PRE. B: activation interacting with transcription factor/s on 
alternative response element (RE) DNA site. P4: progester-
one; PolII: polymerase II; PR: progesterone receptor; PRE: 
progesterone response elements; TF: transcription factor.Journal of Experimental & Clinical Assisted Reproduction 2006, 3:4 http://www.jexpclinassistreprod.com/content/3/1/4
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moter. The luciferase reporter gene driven by MMP pro-
moter will be used. To examine the transcriptional
regulation of MMP gene expression by progesterone in the
trophoblast, full-length (control) or deleted human MMP
promoter-luciferase construct will be transiently trans-
fected into trophoblast cells and treated with increasing
concentrations of progesterone for 24 h. As trophoblast
cells produce a high level of progesterone endogenously,
we will next use a progesterone antagonist, RU486, to
indirectly examine the effects of progesterone on MMP
promoter activity in trophoblast cells. To further confirm
the role of progesterone in the trophoblast expression of
MMP, the endogenous production of progesterone will be
inhibited by the addition of aminoglutethimide (AGT)
(AGT is an inhibitor of cholesterol side chain cleavage
(P450) enzyme).
Part B
The physiological effects of progesterone are mediated
through a specific nuclear receptor protein. Two major
isoforms of PR, namely PR-A and PR-B, have been
described. To further evaluate the role of human PR-A and
PR-B in mediating progesterone action at the MMP tran-
scriptional level, the human PR-A and PR-B expression
vectors will be co-transfected into trophoblast cells with
the full-length (control) or deleted human MMP pro-
moter-luciferase constructs. The same set of experiments
described in part A will be conducted.
Specific aim 2: Identification of transcription binding sites 
and transcription factors involved in progesterone 
modulation: relative roles of progesterone receptor 
isoforms
Specific Aim 1 will provide a physical determination of
the site(s) present in the MMP promoter that regulate the
transcriptional response to progesterone. We will screen
these sites for potential transcription factors with the
TransFac/TESS databases (24). These search algorithms
predict potential transcription factors based on similari-
ties with defined binding motifs. The validity of candidate
transcription factors will then be assessed using electro-
phoretic mobility shift assays (EMSA), chromatin
immuno-precipitation (ChIP) and co-transfection. For
EMSA, labeled oligonucleotides corresponding to the
physically identified progesterone regulatory elements in
the MMP promoter will be incubated with nuclear extracts
from treated (progesterone) and untreated trophoblast
cells. DNA-protein complexes will be resolved from
unbound oligonucleotides by non-denaturating gel elec-
trophoresis and autoradiography. Sequence specificity of
nuclear protein/oligonucleotide interaction will be con-
firmed by competition with cold oligonucleotide and by
site-specific mutagenesis of the core transcription factor
binding sequence. Confirmation of the identity of the
transcription factors exhibiting sequence-specific interac-
tion with the oligonucleotides will be determined using
antibody supershift EMSA, in which antibodies to the can-
didate transcription factors are included in the incubation
mix. Formation of antibody/transcription factor com-
plexes with the oligonucleotide leads to a further decrease
in electrophoretic mobility (hence "supershift").
ChIP is a powerful technique that demonstrates occu-
pancy of regulatory elements in gene promoters within
the genomic context, thus demonstrating that the intrinsic
gene is regulated by these factors. DNA from control and
P-treated cells is isolated, sheared by ultrasonication and
immuno-precipitated with antibodies to the specific tran-
scription factors. Following protein digestion, the
immuno-precipitated DNA fragments are amplified by
PCR and sequenced to confirm recovery of the desired
sequence. Appropriate controls are used at each step of the
process and relative degrees of occupancy can be deter-
mined by densitometry of biotinylated PCR amplification
products.
To functionally confirm that the identified transcription
factors actually regulate MMP transcription, we will per-
form co-transfection of the appropriate MMP luciferase
reporter constructs with increasing concentrations of
expression plasmids encoding the identified transcription
factors.
Implications of the hypothesis
The process of translation of fundamental research to
development of pharmaceutical therapeutics depends
upon new approaches. We propose that PR is capable of
functioning also as transcription factor independent of
the presence of the PRE. The identification of additional
endogenous PR target genes makes it possible to further
explore the signaling mechanisms by which progesterone
regulates biological actions.
The concepts of ligand-driven conformational diversity
and selective tissue actions can be exploited in the future
for drug development that will selectively regulate orphan
receptors from the nuclear receptor family.
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